Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C21H16F3N3O3.ClH |
| Molecular Weight | 451.826 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.FC(F)(F)OC1=CC=C(C=C1)C2=CC=C3OCCN(CC4=NC=CC=N4)C(=O)C3=C2
InChI
InChIKey=ZRYHNOXHGYUHFF-UHFFFAOYSA-N
InChI=1S/C21H16F3N3O3.ClH/c22-21(23,24)30-16-5-2-14(3-6-16)15-4-7-18-17(12-15)20(28)27(10-11-29-18)13-19-25-8-1-9-26-19;/h1-9,12H,10-11,13H2;1H
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Design and modular parallel synthesis of a MCR derived alpha-helix mimetic protein-protein interaction inhibitor scaffold. | 2006-03-15 |
|
| Substituted 1,4-benzodiazepine-2,5-diones as alpha-helix mimetic antagonists of the HDM2-p53 protein-protein interaction. | 2006-03 |
|
| Structure-based design, synthesis, and biological evaluation of novel 1,4-diazepines as HDM2 antagonists. | 2005-04-01 |
|
| Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells. | 2005-02-24 |
Patents
Sample Use Guides
Phase 3 clinical trial designed to determine the efficacy, safety, and tolerability of the late sodium current inhibitor eleclazine in shortening the corrected QT (QTcF) interval in subjects with type 3 Long QT Syndrome (LQT3). 41 subjects with genotype-confirmed LQT3 received a 48 mg oral loading dose of eleclazine followed by 12 weeks of treatment with 3 mg oral eleclazine once daily and then 12 weeks of treatment with 6 mg oral eleclazine once daily.
Route of Administration:
Oral
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
90479986
Created by
admin on Mon Mar 31 20:35:52 GMT 2025 , Edited by admin on Mon Mar 31 20:35:52 GMT 2025
|
PRIMARY | |||
|
1448754-43-5
Created by
admin on Mon Mar 31 20:35:52 GMT 2025 , Edited by admin on Mon Mar 31 20:35:52 GMT 2025
|
PRIMARY | |||
|
1622226-81-6
Created by
admin on Mon Mar 31 20:35:52 GMT 2025 , Edited by admin on Mon Mar 31 20:35:52 GMT 2025
|
NON-SPECIFIC STOICHIOMETRY | |||
|
4R1JP3Q4HI
Created by
admin on Mon Mar 31 20:35:52 GMT 2025 , Edited by admin on Mon Mar 31 20:35:52 GMT 2025
|
PRIMARY | |||
|
DBSALT002187
Created by
admin on Mon Mar 31 20:35:52 GMT 2025 , Edited by admin on Mon Mar 31 20:35:52 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
